Bone Abstracts

Objectives: We aimed to analyze bone mineralization in postmenopausal women of Southern Apulia and to evaluate the effect of obesity-related phenotypes as BMI ≥30 kg/m2, diabetes, hypertension and cardiovascular diseases.Methods: The PROF project is a population-based study on 3.356 subjects (40–99 years) analyzed by phalangeal quantitative ultrasound (QUS) to evaluate bone mineral status. A total of 2.756 postmenopausal women were ...

Objectives: Type 2 diabetes mellitus (T2DM) is associated to an higher risk of fractures despite a normal or increased bone mineral density measured by dual-energy X-ray absorptiometry (DXA).The purpose of this 3-years longitudinal study was to assess the changes of quantitative ultrasound (QUS) parameters in a group of postmenopausal women with T2DM and in healthy controls.Materials and method: The analyses were performed on a gro...

Background: Osteoporosis is a leading cause of morbidity in patients affected by β-thalassaemia major (TM) and intermediate thalassaemia (TI). Appropriate supportive care and identification of long-term sequels of therapy are important in thalassaemic patients. As low bone mineral quality (BMQ) in patients can be considered a marker of possible degeneration to osteopenia and osteoporosis in adulthood, we evaluated bone features in a young population followed at ‘A. P...

Introduction: Currently, the only available method to reliably predict osteoporotic fractures is represented by bone mineral density (BMD) measurements on proximal femur or spine, which require the use of X-rays. Aim of this study is to illustrate working principles and feasibility of a new ultrasound (US) method for bone densitometry and osteoporosis diagnosis applicable on both proximal femur and spine.Methods: A new fully automatic algorithm was devel...

Osteoporosis is a leading cause of morbidity in patients affected by β-thalassaemia major (TM) and intermediate thalassaemia (TI). Appropriate supportive care and identification of long-term sequels of therapy are important in thalassaemic patients. As low bone mineral quality (BMQ) in patients can be considered a marker of possible degeneration to osteopenia and osteoporosis in adulthood, we evaluated bone features in a young population followed at ‘A. Perrino’...

Introduction: Currently, osteoporosis is mainly diagnosed through dual-enargy X-ray absorptiometry (DXA). However, DXA cannot be used for early diagnoses through population mass screenings because of issues related to ionizing radiation employment. Aim of this study is to perform a preliminary clinical validation of a new ultrasound (US)-based method for vertebral densitometry.Methods: A total of 270 women were included in this study according to the fol...

Introduction: Recently reported high incidences of hip fractures emphasize the need of more effective methods for osteoporosis diagnosis, currently performed essentially by dual-energy X-ray absorptiometry (DXA) examinations of the proximal femur. However, high costs and radiation-related issues do not allow DXA employment for population mass screenings. Aim of this study is to carry out a preliminary clinical validation of a new ultrasound (US)-based method to perform femoral...

Introduction: Denosumab, a fully human monoclonal antibody to RANK ligand, effectively reduces bone resorption by inhibiting RANK-L binding to RANK. We aimed to evaluate the efficacy of denosumab in post-menopausal women, by monitoring the evolution of different parameters of bone health: T-score, morphometry, osteocalcin and β-Ctx.Methods: A 34 women with severe postmenopausal osteoporosis, characterized by multiple vertebral fractures wer...

Reduced bone mineral density (BMD) has been reported to adversely affect health related quality of life (HRQoL) also in postmenopausal women without vertebral fracture. To date no data exist in literature about any possible influences of quantitative ultrasonography (QUS) on HRQoL. This study aimed to assess whether QUS parameters at calcaneous may be associated with HRQoL.In 1812 ambulatory postmenopausal women aged 60 years or over, referred by their f...

Background: Cabozantinib (CBZ) is a receptor tyrosine kinase inhibitor with activity against MET, VEGFR2, FLT3, c-KIT, and RET. Pre-clinical studies in models of prostate cancer bone metastasis demonstrated that CBZ treatment induced both a suppression of tumour growth and an alteration in bone remodelling, suggesting that both tumour and bone microenvironment represented potential CBZ targets. This is the first study exploring the potential direct activity of CBZ in bone usin...